SIS
ARQT icon

Sound Income Strategies’s Arcutis Biotherapeutics ARQT Stock Holding History

Sound Income Strategies’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-186
Closed -$4.48K – 602
2026
Q1 		$4.48K Hold
186
– – ﹤0.01% 1875
2025
Q4 		$4.81K Buy
+186
New +$4.76K ﹤0.01% 1827

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
JAFL
Jay A. Fishman Ltd Troy, Michigan $1.26B AUM 31.39% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Sound Income Strategies's ARQT Position: Q2 2026 in Review

Sound Income Strategies sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 186 shares — an estimated $4.48K sold.

Sound Income Strategies first reported a position in ARQT in Q4 2025 and held it in 2 quarters. The position peaked at $4.81K in Q4 2025. 63 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Sound Income Strategies reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 186 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.48K.
  • Sound Income Strategies first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's Arcutis Biotherapeutics position peaked at $4.81K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.